Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center — Tampa, Florida

Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center is a clinical research site located in Tampa, Florida, United States 33612.

Crixeo Health Trust Score: 67/100 (FAIR). This profile has not yet been claimed by the site owner.

Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center has participated in 6 clinical trials with 5 currently active.

Therapeutic areas: Breast Cancer, Breast Neoplasms, Melanoma.

Sponsors: Eli Lilly and Company, Pfizer, Bristol-Myers Squibb.

Sponsor Feasibility Report

Trust Score: 67/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center?

Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center has a Crixeo Trust Score of 67/100 (FAIR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center conducted?

Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center has 6 clinical trials on record, with 5 currently active. Their work covers Breast Cancer, Breast Neoplasms, Melanoma.

Is Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center accredited by Crixeo Health?

Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Moffitt Cancer Center, Richard M. Shulze Family Foundation Outpatient Center?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.